Trial site
Synexus Polska Sp. z o.o.
Gdynia, 81-537, PolandEU-13 widening countryNot linked to an institution yet
- 20running trials
- 16closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 328 trials
- Phase 27 trials
- Phase 2/31 trial
- Status
- Completed16 trials
- Active, not recruiting12 trials
- Recruiting8 trials
- Lead sponsor
- Ipsen3 trials
- Pfizer3 trials
- Alumis Inc2 trials
- Ascletis Pharma (China) Co. Ltd.2 trials
- AstraZeneca2 trials
- and 23 more
Running trials
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
2025-520587-18-00· Phase 2· Supernus Pharmaceuticals Inc.· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus
2025-524514-28-00· Phase 2· Corxel Pharmaceuticals Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· Phase 3· Pfizer· Source
Active, not recruiting
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· Phase 3· Pfizer· Source
Active, not recruiting
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· Phase 2· Kymera Therapeutics, Inc.· Source
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060· Phase 3· AstraZeneca· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Recruiting
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis
2023-510338-10-00· Phase 3· Laboratorios Ojer Pharma S.L.· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060· Phase 2· Ipsen· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00· Phase 3· Akero Therapeutics Inc.· Source
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· Phase 2· Nektar Therapeutics· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH
2024-510626-89-00· Phase 3· Madrigal Pharmaceuticals Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis
2024-512417-41-00· Phase 3· Xentria Inc.· Source
Completed
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
NCT06602219· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source
Completed
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· Phase 3· Alumis Inc· Source
Completed
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis
2023-503790-37-00· Phase 3· Curateq Biologics Private Limited· Source
Completed
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· Phase 3· Boehringer Ingelheim· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· Phase 3· Takeda· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· Phase 3· Ipsen· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457· Phase 3· Ipsen· Source
Completed
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis
NCT05853354· Phase 3· Shandong Boan Biotechnology Co. Ltd.· Source
Completed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642· Phase 3· Hoffmann-La Roche· Source
Completed
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
NCT05477524· Phase 3· Pfizer· Source
Completed
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259· Phase 2· AstraZeneca· Source
Completed
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
NCT03989206· Phase 3· Galderma R&D· Source
Completed
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· Phase 3· Bristol-Myers Squibb· Source
Completed
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· Phase 3· Celgene International II SARL· Source
Completed
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease
2023-510426-33-00· Phase 3· Celgene International II S.a.r.l.· Source
Report an error